Potential Lymphangiogenesis Therapies: Learning from Current Antiangiogenesis Therapies-A Review

Overview

Journal Med Res Rev

Publisher Wiley

Specialties General Medicine
Pharmacology

Date 2018 Mar 13

PMID 29528507

Citations 29

Authors

Michael Yamakawa

Susan J Doh

Samuel M Santosa

Mario Montana

Ellen C Qin

Hyunjoon Kong

Kyu-Yeon Han

Charles Yu

Mark I Rosenblatt

Andrius Kazlauskas

Jin-Hong Chang

Dimitri T Azar

Affiliations

Soon will be listed here.

Abstract

In recent years, lymphangiogenesis, the process of lymphatic vessel formation from existing lymph vessels, has been demonstrated to have a significant role in diverse pathologies, including cancer metastasis, organ graft rejection, and lymphedema. Our understanding of the mechanisms of lymphangiogenesis has advanced on the heels of studies demonstrating vascular endothelial growth factor C as a central pro-lymphangiogenic regulator and others identifying multiple lymphatic endothelial biomarkers. Despite these breakthroughs and a growing appreciation of the signaling events that govern the lymphangiogenic process, there are no FDA-approved drugs that target lymphangiogenesis. In this review, we reflect on the lessons available from the development of antiangiogenic therapies (26 FDA-approved drugs to date), review current lymphangiogenesis research including nanotechnology in therapeutic drug delivery and imaging, and discuss molecules in the lymphangiogenic pathway that are promising therapeutic targets.

Citing Articles

Targeting glycolytic reprogramming by tsRNA-0032 for treating pathological lymphangiogenesis.

Ye F, Zhang Z, Shi L, Lu S, Li X, Mu W Cell Death Dis. 2025; 16(1):51.

PMID: 39870617 PMC: 11772812. DOI: 10.1038/s41419-025-07366-w.

Scopoletin: a review of its pharmacology, pharmacokinetics, and toxicity.

Gao X, Li X, Zhang C, Bai C Front Pharmacol. 2024; 15:1268464.

PMID: 38464713 PMC: 10923241. DOI: 10.3389/fphar.2024.1268464.

Modeling lymphangiogenesis: Pairing in vitro and in vivo metrics.

Suarez A, Hammel J, Munson J Microcirculation. 2023; 30(2-3):e12802.

PMID: 36760223 PMC: 10121924. DOI: 10.1111/micc.12802.

Lymphangiogenesis Guidance Mechanisms and Therapeutic Implications in Pathological States of the Cornea.

Patnam M, Dommaraju S, Masood F, Herbst P, Chang J, Hu W Cells. 2023; 12(2).

PMID: 36672254 PMC: 9856498. DOI: 10.3390/cells12020319.

KRAS mutations as essential promoters of lymphangiogenesis via extracellular vesicles in pancreatic cancer.

Pirlog R, Calin G J Clin Invest. 2022; 132(14).

PMID: 35838046 PMC: 9282924. DOI: 10.1172/JCI161454.

References

Kim K, Li B, Houck K, Winer J, Ferrara N . The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992; 7(1):53-64. DOI: 10.3109/08977199209023937. View

Kaipainen A, Korhonen J, Pajusola K, Aprelikova O, Persico M, Terman B . The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med. 1993; 178(6):2077-88. PMC: 2191284. DOI: 10.1084/jem.178.6.2077. View

Gurung H, Carr M, Carr D . Cornea lymphatics drive the CD8 T-cell response to herpes simplex virus-1. Immunol Cell Biol. 2016; 95(1):87-98. PMC: 5209249. DOI: 10.1038/icb.2016.80. View

Naumov G, Nilsson M, Cascone T, Briggs A, Straume O, Akslen L . Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009; 15(10):3484-94. PMC: 2893040. DOI: 10.1158/1078-0432.CCR-08-2904. View

Zhang L, Li G, Sessa R, Kang G, Shi M, Ge S . Angiopoietin-2 Blockade Promotes Survival of Corneal Transplants. Invest Ophthalmol Vis Sci. 2017; 58(1):79-86. PMC: 5231909. DOI: 10.1167/iovs.16-20485. View

Wang D, Tan C, Xiao F, Zou L, Wang L, Wei Y . The "inherent vice" in the anti-angiogenic theory may cause the highly metastatic cancer to spread more aggressively. Sci Rep. 2017; 7(1):2365. PMC: 5443774. DOI: 10.1038/s41598-017-02534-1. View

Gordon A, Fleagle J, GUTHRIE D, Parkin D, Gore M, Lacave A . Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19(14):3312-22. DOI: 10.1200/JCO.2001.19.14.3312. View

Kang G, Ecoiffier T, Truong T, Yuen D, Li G, Lee N . Intravital Imaging Reveals Dynamics of Lymphangiogenesis and Valvulogenesis. Sci Rep. 2016; 6:19459. PMC: 4726360. DOI: 10.1038/srep19459. View

Preynat-Seauve O, Contassot E, Schuler P, Piguet V, French L, Huard B . Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process. Cancer Res. 2007; 67(10):5009-16. DOI: 10.1158/0008-5472.CAN-06-4494. View

10.

Murakami J, Ishii M, Suehiro F, Ishihata K, Nakamura N, Nishimura M . Vascular endothelial growth factor-C induces osteogenic differentiation of human mesenchymal stem cells through the ERK and RUNX2 pathway. Biochem Biophys Res Commun. 2017; 484(3):710-718. DOI: 10.1016/j.bbrc.2017.02.001. View

11.

Miller K, Chap L, Holmes F, Cobleigh M, Marcom P, Fehrenbacher L . Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005; 23(4):792-9. DOI: 10.1200/JCO.2005.05.098. View

12.

Saharinen P, Tammela T, Karkkainen M, Alitalo K . Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 2004; 25(7):387-95. DOI: 10.1016/j.it.2004.05.003. View

13.

Baker C, Kedar D, McCarty M, Tsan R, Weber K, Bucana C . Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol. 2002; 161(3):929-38. PMC: 1867249. DOI: 10.1016/S0002-9440(10)64253-8. View

14.

Miles D, Chan A, Dirix L, Cortes J, Pivot X, Tomczak P . Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28(20):3239-47. DOI: 10.1200/JCO.2008.21.6457. View

15.

Dickler M, Barry W, Cirrincione C, Ellis M, Moynahan M, Innocenti F . Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016; 34(22):2602-9. PMC: 5012690. DOI: 10.1200/JCO.2015.66.1595. View

16.

Adamczyk L, Gordon K, Kholova I, Meijer-Jorna L, Telinius N, Gallagher P . Lymph vessels: the forgotten second circulation in health and disease. Virchows Arch. 2016; 469(1):3-17. PMC: 4923112. DOI: 10.1007/s00428-016-1945-6. View

17.

Leu A, Berk D, Lymboussaki A, Alitalo K, Jain R . Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000; 60(16):4324-7. View

18.

Saito Y, Nakagami H, Kaneda Y, Morishita R . Lymphedema and therapeutic lymphangiogenesis. Biomed Res Int. 2013; 2013:804675. PMC: 3810055. DOI: 10.1155/2013/804675. View

19.

Kamath S, Buolamwini J . Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev. 2006; 26(5):569-94. DOI: 10.1002/med.20070. View

20.

Motzer R, Hutson T, McCann L, Deen K, Choueiri T . Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014; 370(18):1769-70. DOI: 10.1056/NEJMc1400731. View